Concentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure
Motiwala SR, Gaggin HK, Gandhi PU, Belcher A, Weiner RB, Baggish AL, Szymonifka J, Januzzi JL. Concentrations of Highly Sensitive Cardiac Troponin-I Predict Poor Cardiovascular Outcomes and Adverse Remodeling in Chronic Heart Failure. Journal Of Cardiovascular Translational Research 2015, 8: 164-172. PMID: 25777344, DOI: 10.1007/s12265-015-9618-4.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiomarkersChi-Square DistributionChronic DiseaseDisease ProgressionFemaleHeart FailureHumansKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardiumNatriuretic Peptide, BrainNecrosisOdds RatioPeptide FragmentsPhenotypePredictive Value of TestsPrognosisProportional Hazards ModelsRandomized Controlled Trials as TopicRetrospective StudiesRisk FactorsSystoleTime FactorsTroponin IVentricular Dysfunction, LeftVentricular Function, LeftVentricular RemodelingConceptsLV systolic dysfunctionChronic heart failureHeart failureLV remodelingSerial measurementsHigh-risk clinical featuresLower CV event ratesCV event ratesDeleterious LV remodelingIndependent risk informationPoor cardiovascular outcomesPoor CV outcomesProgressive LV remodelingSensitive cardiac troponinMajority of patientsSignificant myocardial necrosisSensitive troponin assaysPg/mLCV outcomesHsTnI concentrationsCardiovascular eventsCardiovascular outcomesSystolic dysfunctionAdverse remodelingClinical featuresGalectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction
Gandhi PU, Motiwala SR, Belcher AM, Gaggin HK, Weiner RB, Baggish AL, Fiuzat M, Rocca H, Januzzi JL. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. American Heart Journal 2015, 169: 404-411.e3. PMID: 25728731, DOI: 10.1016/j.ahj.2014.12.012.Peer-Reviewed Original ResearchConceptsElevated galectin-3Mineralocorticoid receptor antagonistsCV event ratesMRA therapyGalectin-3 concentrationsQuality of lifeGalectin-3CV eventsHeart failureMRA useLeft ventricular systolic dysfunctionMineralocorticoid receptor antagonist useTreatment-related adverse eventsEvent ratesBaseline galectin-3Ventricular remodeling indexChronic heart failureOutcomes of patientsReduced ejection fractionVentricular systolic dysfunctionReceptor antagonist useSignificant renal dysfunctionFirst CV eventHeart failure biomarkersChronic HFrEF